Efficacy of avibactam/ceftazidime in patients with carbapenem-resistant pseudomonas infection: A retrospective multicenter study
Latest Information Update: 27 Dec 2016
Price :
$35 *
At a glance
- Drugs Avibactam/ceftazidime (Primary)
- Indications Pseudomonal infections
- Focus Therapeutic Use
- 27 Dec 2016 New trial record
- 30 Oct 2016 Results presented at the IDWeek 2016